Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei 112, Taiwan, ROC.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3180-5. doi: 10.1016/j.bmcl.2013.04.002. Epub 2013 Apr 10.
This study evaluated the tumor targeting and therapeutic efficacy of a novel theranostic agent (131)I-labeled immuno-gold-nanoparticle ((131)I-C225-AuNPs-PEG) for high epidermal growth factor receptor (EGFR)-expressed A549 human lung cancer. Confocal microscopy demonstrated the specific uptake of C225-AuNPs-PEG in A549 cells. (131)I-C225-AuNPs-PEG induced a significant reduction in cell viability, which was not observed when incubated with AuNPs-PEG and C225-AuNPs-PEG. MicroSPECT/CT imaging of tumor-bearing mice after intravenous injection of (123)I-C225-AuNPs-PEG revealed significant radioactivity retention in tumor suggested that (131)I-labeled C225-conjugated radioimmuno-gold-nanoparticles may provide a new approach of targeted imaging and therapy towards high EGFR-expressed cancers.
本研究评估了一种新型治疗诊断试剂（131）I 标记免疫金纳米颗粒（（131）I-C225-AuNPs-PEG）对高表皮生长因子受体（EGFR）表达的 A549 人肺癌的肿瘤靶向和治疗效果。共聚焦显微镜显示 C225-AuNPs-PEG 特异性摄取 A549 细胞。（131）I-C225-AuNPs-PEG 导致细胞活力显著降低，而与 AuNPs-PEG 和 C225-AuNPs-PEG 孵育时则未观察到这种情况。荷瘤小鼠静脉注射（123）I-C225-AuNPs-PEG 后进行 MicroSPECT/CT 成像，显示肿瘤中存在显著的放射性滞留，表明（131）I 标记的 C225 结合放射性免疫金纳米颗粒可能为高 EGFR 表达癌症的靶向成像和治疗提供新方法。
